Scilex Holding Company
Striving to Revolutionize the World of Non-Opioid Pain Management
Striving to Revolutionize the World of Non-Opioid Pain Management
Scilex Holding Company is a Nasdaq-listed company founded in 2012, with a mission to revolutionize non-opioid pain management. The company's lead product, ZTlido® (lidocaine topical system) 1.8%, offers innovative delivery and adhesion technology for pain relief associated with Post-Herpetic Neuralgia. In addition to ZTlido®, the company has acquired GLOPERBA® and ELYXYB®, FDA-approved products for gout flares and acute migraine treatment, respectively. The recent $100.00M Post-IPO Debt investment on 11 June 2024 from Perigrove and Graf Holdings underscores investor confidence in Scilex's potential. The commitment to harnessing advanced delivery technologies and the development of innovative product candidates like SEMDEXA™ and SP-103 positions Scilex as a key player in the non-opioid pain management industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $100.00M | 2 | Perigrove, Graf Holdings | 11 Jun 2024 |
| Post-IPO Equity | $15.00M | - | 24 Apr 2024 | |
| Post-IPO Equity | $10.00M | - | 29 Feb 2024 | |
| Post-IPO Debt | $25.00M | 1 |
|
21 Mar 2023 |
| Venture Round | $479.93K | - | 17 May 2016 |
We care about your data, and we'd love to use cookies make your experience better.
